Philikos, a privately held biotechnology company based in the Netherlands, is developing antibody-based therapies for the treatment of severe immune disorders. The company’s platform offers a compound, T-Guard, that rebalances the immune system by depleting activated T cells and NK cells, enabling patients with autoimmune diseases such as scleroderma to achieve restored immune functions and improved long-term health outcomes. Philikos is backed by early-stage investors: Oost NL, Essential Investments, and Radboud University Medical Center (Radboudumc), with which it also maintains a strong research collaboration.

More information: www.philikos.com